These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3122267)

  • 1. Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.
    Maxon HR; Deutsch EA; Thomas SR; Libson K; Lukes SJ; Williams CC; Ali S
    Radiology; 1988 Feb; 166(2):501-7. PubMed ID: 3122267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
    Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
    Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
    J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
    Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.
    Lin WY; Lin CP; Yeh SJ; Hsieh BT; Tsai ZT; Ting G; Yen TC; Wang SJ; Knapp FF; Stabin MG
    Eur J Nucl Med; 1997 Jun; 24(6):590-5. PubMed ID: 9169563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
    Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
    Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
    Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP.
    Samaratunga RC; Thomas SR; Hinnefeld JD; Von Kuster LC; Hyams DM; Moulton JS; Sperling MI; Maxon HR
    J Nucl Med; 1995 Feb; 36(2):336-50. PubMed ID: 7830140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S; Bohuslavizki KH
    MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma.
    Virotta G; Medolago G; Arrigoni S; Butti I; Bertocchi C
    Tumori; 1997; 83(2):563-5. PubMed ID: 9226022
    [No Abstract]   [Full Text] [Related]  

  • 20. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Liepe K; Kropp J; Hliscs R; Franke WG
    Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.